Similarly, CiRS-7 is a promising biomarker for predicting the prognosis of CRC patients, and it has the potential to be used as a therapeutic target for lowering the activity of EGFR-RAF1 in CRC patients [168]. This evidence concerns the gene EGFR and colorectal carcinoma.